Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
Nelly Joseph-MathurinJorge J Llibre-GuerraYan LiAustin A McCulloughCarsten HofmannJakub WojtowiczEthan ParkGuoqiao WangGregory M PreboskeQing WangBrian A GordonCharles D ChenShaney FloresNeelum T AggarwalSarah B BermanThomas D BirdSandra E BlackBret BorowskiWilliam S BrooksJasmeer P ChhatwalRoger ClarnetteCarlos CruchagaAnne M FaganMartin FarlowNick C FoxSerge GauthierJason HassenstabDiana A HobbsKaren C HoldridgeLawrence S HonigRuss C HornbeckGing-Yuek R HsiungClifford R JackIvonne Z Jimenez-VelazquezMathias JuckerGregory KleinJohannes LevinMichele ManciniMario MasellisNicole S McKayCatherine J MummeryJohn M RingmanHiroyuki ShimadaB Joy SniderKazushi SuzukiDavid WallonChengjie XiongRoy YaariEric McDadeRichard J PerrinRandall J BatemanStephen P SallowayTammie L S BenzingerDavid B Cliffordnull nullPublished in: Annals of neurology (2022)
In DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA-E risk, with additional risk for individuals APOE-ɛ4(+) or with microhemorrhage. ARIA-E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729-744.